Brokerages Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Target Price at $18.30

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $18.30.

Several equities research analysts recently issued reports on the stock. HC Wainwright cut their price objective on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, March 21st. Wedbush reaffirmed an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Morgan Stanley decreased their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. Bank of America reduced their target price on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Finally, Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They set a “buy” rating and a $17.00 price objective for the company.

Y-mAbs Therapeutics Price Performance

YMAB stock opened at $4.81 on Wednesday. Y-mAbs Therapeutics has a 1 year low of $4.25 and a 1 year high of $17.78. The firm has a market capitalization of $217.50 million, a PE ratio of -8.91 and a beta of 0.65. The business has a 50 day simple moving average of $5.58 and a 200-day simple moving average of $9.47.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The company had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. During the same quarter in the previous year, the company earned ($0.02) earnings per share. On average, equities research analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 22.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State Street Corp boosted its position in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after acquiring an additional 405,169 shares in the last quarter. Barclays PLC boosted its holdings in Y-mAbs Therapeutics by 433.4% in the third quarter. Barclays PLC now owns 69,222 shares of the company’s stock valued at $910,000 after purchasing an additional 56,244 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Y-mAbs Therapeutics by 6.2% in the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Intech Investment Management LLC purchased a new position in Y-mAbs Therapeutics in the third quarter valued at approximately $133,000. Finally, Caligan Partners LP raised its holdings in Y-mAbs Therapeutics by 105.3% during the third quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after purchasing an additional 613,175 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.